Listed alphabetically by surname.
Vicki Anastasi - Vice President and Global Head, Medical Devices and Diagnostics Research, ICON.
Ms. Anastasi provides leadership to create and foster priority relationships in the medical device and diagnostic marketplace, developing customized programs to meet medical device client needs. She has over twenty five years of experience in the medical device industry, with over fifteen years specifically focused on global medical device strategic consulting.
Prior to joining the company in 2007, she held senior management roles for medical device companies focused in orthopedics, cardiovascular, general hospital, and general surgical devices. In diagnostics, she held senior positions at companies involved in the development of infectious disease and genetic-based products.
She is actively involved in medical device industry groups, including Advamed, OCTANe, MassMedic and MDMA, where she regularly speaks and participates in medical device focused panels and discussions.
Michael Beebe - Partner, Senior Vice President, ADVI
Michael Beebe, Senior Vice President, joined ADVI in 2008. Mr. Beebe advises clients on all aspects of reimbursement and strategic policy planning, including specific coding strategies in the physician office and the hospital or other health care provider settings. He directs ADVI’s device and diagnostic practices. Mr. Beebe has a Bachelor of Arts from Penn State University and a Master’s Degree from Boston University.
Mr. Beebe spent 14 years at the AMA prior to joining ADVI; his most recent position was Director of CPT. He was also a central participant in AMA advocacy efforts involving public and private coverage, coding and reimbursement issues; including provider class action litigation, CMS physician payment negotiations, and local coverage determinations. In addition, Mr. Beebe was a Senior Social Scientist in Physician Payment Systems where he was primary staff to the AMA/Specialty Society RVS Update Committee (RUC).
He is responsible for or involved in many of the most seminal product and service coding decisions, such as molecular and companion diagnostics – created MAAA and NGS coding nomenclatures, spinal techniques, vaccines, tele-monitoring, wound Care and skin substitutes, and cardiac procedures.
Bill Carpou - President & CEO, OCTANe
Bill has held many key positions at technology companies such as Xerox and IKON, and created distribution channels and customer solutions for products manufactured by Canon, Ricoh, and H-P. Both companies also provided an opportunity for Bill to lead distressed operations back to profitability and interact with investors, including several Wall Street investment banks. Additionally, he led several acquisitions and the creation of strategic partnerships. Bill was with Merrill Lynch earlier in his career, and more recently, held an executive position within The Blackstone Group, one of the leading global private equity firms. In that role Bill led the successful growth and transformation of a key portfolio company. He has broad sales and marketing experience and during 2014, worked with several startups to provide advisory services focused to revenue growth, and increasing both profitability and overall enterprise value.
Kevin J. Cousins - VP and Chief Financial Officer, Sequent Medical
Kevin joined Sequent in January 2014, and brings more than 30 years of experience in public accounting and senior financial executive roles, primarily with medical device companies. From September 2010 to December 2012, Kevin served as the VP of Finance & CFO with Neomend, Inc. Neomend developed and commercialized a novel hydrogel surgical sealant used in minimally invasive and laparoscopic thoracic procedures. Experiencing rapid revenue growth, the company was acquired by the Davol Division of CR Bard in October of 2012.
Prior to Neomend, Kevin served as the VP of Finance & CFO for SenoRx, Inc. from 2001 to 2010. SenoRx designed, developed, manufactured and marketed minimally invasive devices for the diagnosis and treatment of breast cancer. The company completed its Initial Public Offering (IPO) in March of 2007 and was acquired by CR Bard in July 2010.
Prior to SenoRx, Kevin served in a variety of financial leadership roles at various companies, including Biopsys Medical (acquired by J&J). Kevin began his public accounting career in 1977 with KPMG, after earning his B.A. in Business Administration from California State University, Fullerton. He earned his CPA certification in 1980 and holds a Master Degree in Taxation from Golden Gate University.
Louis C. Cullman – Partner, K&L Gates.
Louis is a partner in the Orange County office of K&L Gates LLP specializing in intellectual property (IP) law where he manages the transactional IP group. His practice has a strong life sciences focus and concentrates on transactional IP for pharmaceutical and medical device companies including patent procurement, technology transfer and Bayh-Dole issues, merger and acquisition-related due diligence, freedom to operate analyses, non-infringement and invalidity opinions, Hatch-Waxman-related client counseling and litigation support. Louis regularly represents pharmaceutical and medical device companies in matters related to product life cycle management, patent litigation strategy and merger and acquisition IP due diligence. Prior to attending law school at the Southwestern University School of Law, Louis was a licensed Clinical Microbiologist and co-founded and directed an infectious disease laboratory and diagnostic device manufacturing company in Southern California. He has extensive technical experience in the design and manufacturing of in vitro diagnostic devices for infectious diseases, immunology and biochemistry.
Andrew Douglas - Partner, Knobbe, Martens, Olson & Bear LLP
Andrew M. Douglas is a partner in Knobbe, Martens, Olson, & Bear's Orange County Office. He specializes in client practice, including patents, trademarks, and other forms of intellectual property protection. Mr. Douglas’ practice includes patent portfolio management, general counseling on licensing, trademarks, and other related issues. Mr. Douglas currently represents clients in a variety of technologies, including ophthalmic devices and methods, cardiovascular devices and methods, orthopedic devices and methods, automotive technologies, solar energy applications, and other mechanical engineering related technologies. Prior to joining the firm, Mr. Douglas worked as a product engineer in the recording head component division of Seagate Technology in Bloomington, Minnesota from 1994 to 1998. Mr. Douglas joined the firm in 2000 and became a partner in 2006.
Bruce Feuchter - Shareholder, Stradling
Bruce Feuchter is a shareholder in Stradling's corporate law practice. He is a member of the firm’s board of directors, has practiced at Stradling since 1981. He specializes in corporate securities, as well as corporate and general finance transactions. His clients include investors and both publicly and privately held companies at various stages of their existence. A highly sought after adviser and counselor, Mr. Feuchter has developed a solid reputation for his ability to see early stage companies through to successful exits. Mr. Feuchter also represents many companies in their venture financings and has represented venture capital funds in their investments with emerging growth companies. He is well-known and respected in the emerging growth life science and technology community for representing companies in their initial public offerings.
Paul Grand - Managing Director, RCT Ventures, & Head, MedTech Innovator Accelerator
Grand has more than twenty-five years experience in venture capital and the founding and management of early-stage companies in technology and healthcare. He is responsible for sourcing RCT’s investments in medical devices and representing RCT on the boards of its portfolio companies. Since 1990, Grand has built, operated, recruited management and raised financing for eight high technology, medical device and biotechnology companies.
Grand is actively involved in programs to encourage innovation and technology commercialization and is a frequent speaker, moderator and panelist at healthcare conferences. He serves as producer and emcee for the MedTech Innovator accelerator and competition, which identifies and rewards outstanding early-stage medical device companies. Grand is on the Oversight Committees for the Coulter Translational Research Partnership Programs at USC and University of Washington. He has lectured, served as a reviewer for proof of concept and commercialization-focused funding programs, and mentored students and scientists at numerous universities, including UCLA, Stanford, USC, UCSF, University of Utah, the Keck Graduate Institute and University of Colorado. Grand served as an investment advisor to the LARTA NIH Commercialization Assistance Program for SBIR program awardees.
Michael Hedge - Partner, K&L Gates
Michael is a partner in K&L Gates' Orange County office and co-leader of the firm-wide life science practice. His practice focuses on mergers and acquisitions, venture financing, public offerings, corporate governance and commercial transactions. Mike’s clients range from early stage companies to multi-billion dollar public companies and include some of Orange County’s leading life science companies. Mike is also active in representing underwriters in public offerings, with a particular emphasis on offerings for pharmaceutical and medical device companies.
Harold A. Heitzmann - Ph.D., Vice President, Glaukos
Harold A. Heitzmann, Ph.D. has served as vice president of applied research at Glaukos since January 2007. He has more than 30 years of experience in the development of medical devices at five startup companies and at Edwards Lifesciences Corporation, including three previous positions as vice president. Dr. Heitzmann has led the development of commercial products for blood gas monitoring, angioplasty, intracranial pressure monitoring, electrophysiology, coronary stenting, thrombectomy, venous oxygen saturation monitoring, and antimicrobial catheterization. He holds 18 issued U.S. patents and has taught at University of California, Irvine Extension in the Clinical Trials and Medical Product Development certificate programs. Dr. Heitzmann holds a B.A. from Cornell University and a Ph.D. in molecular biophysics and biochemistry from Yale University, where he co-invented avidin-biotin staining for microscopy.
Patrick Johnson - CEO, BioPhotas
Mr. Johnson is a seasoned executive with P&L leadership in turnarounds, start-ups, emerging companies, as well as companies challenged with mature product life cycles. With a history of repeatedly growing sales and gross margins at double digit growth rates, Patrick has provided leadership in strategic planning, sales, marketing, corporate branding, product positioning and operations. Patrick is a senior executive with 25 years experience leading manufacturing companies in diverse industries including medical, dental, aerospace and motorsports.
His recent leadership experience includes ten years with Pro-Dex, Inc., a publicly-held medical device manufacturer, serving in the roles of Chief Business Development Officer, CEO and President and Board Member. Mr. Johnson left Pro-Dex in early 2010 to start-up a humanitarian relief organization, The WorldBed Project. The charter of this organization was to build strategic alliances with government, NGOs, corporations and individuals to bring badly needed funding to Haiti in the aftermath of the earthquake. Prior to Pro-Dex, Mr. Johnson held senior management positions with Sybron Dental Specialties, Tycom Dental and Dabico, Inc.
Patrick graduated from the University of California with Honors, earning Bachelors of Arts degrees in Philosophy and Legal Studies. Patrick also earned his Masters of Arts in Business Administration from Pepperdine University. Mr. Johnson currently serves as an Entrepreneur in Residence at Chapman University Leatherby Center for Entrepreneurship.
Jeffrey J. Kimbell - President, Jeffrey J. Kimbell & Associates
Jeffrey J. Kimbell, President of Jeffrey J. Kimbell & Associates, represents clients in the life sciences community seeking legislative remedies for their needs. Mr. Kimbell specializes in representing life science companies before the U.S. government. The firm provides strategic solutions to hand-selected clients seeking creation, modification, or proper implementation of public law. Three years after establishing his firm, in January of 2001, Mr. Kimbell was named to President George W. Bush’s Transition Team Advisory Committee for the U.S. Department of Health and Human Services (HHS). He was the only consultant to serve on the Committee.
Prior to establishing Kimbell & Associates, Mr. Kimbell served as the first Executive Director of the Medical Device Manufacturers Association (MDMA) from 1994-1998. While at MDMA, he directed all Washington policy initiatives on behalf of MDMA’s member companies. During his tenure, the association grew from 25 companies to 130, an increase that can be directly attributed to a number of legislative victories, including passage of a landmark bill to overhaul the product approval process at the U.S. Food & Drug Administration.In addition to the handling matters before the U.S Congress, Mr. Kimbell was also responsible for MDMA’s interaction with state and foreign governments and federal agencies of jurisdiction on tax and trade matters. In this capacity, he worked very closely with both the U.S. Department of Commerce and U.S. Trade Representative (USTR). As the principal spokesperson for MDMA, Mr. Kimbell coordinated all communications with the media; the public and private financing communities on Wall Street and related venture capital firms; the U.S. Congress; the White House; HHS; and the FDA.
Prior to MDMA, Mr. Kimbell was a personal aide to former Senator Howard H. Baker, Jr. (R-TN) and personal attaché to former Secretary of State Lawrence S. Eagleburger in the Washington office of the Tennessee-based law firm Baker, Worthington, Crossley & Stansberry. While at Baker-Worthington, Mr. Kimbell tracked legislative activity for a host of Fortune 500 clients.
In June 2006, The Hill recognized Mr. Kimbell as one of the top lobbyists in the medical device field in its “Lobby League.” Mr. Kimbell has contributed to or been interviewed by a host of trade and global news publications and television programs: Bloomberg’s Business News, Bureau of National Affairs (BNA), Congressional Quarterly, Forbes, The New York Times, MX Magazine (also serving on their editorial board), Scripps-Howard, Reuters, Time, The Washington Post, Roll Call, Politico, The Food & Drug Law Journal, and many others. Mr. Kimbell has testified before the U.S. Congress and spoken before numerous industry groups, associations, and educational institutions, including within the last year: Harvard Business School, OCTANe Medical Device & Investor Forum, AAOS Chicago Ophthalmology Summit (ACOS), and Columbia University.
In addition to Jeffrey J. Kimbell & Associates, Mr. Kimbell is Managing Director of Jackalope Real Estate, LLC (Park City, UT) and President of Magnum Entertainment Group, Inc. (Washington, D.C.).
A graduate of Southern Methodist University (SMU) in Dallas, TX, Mr. Kimbell earned his B.A. in Political Science. While at SMU, he worked for U.S. Congressman Sam Johnson (R-TX), a member of the House Ways & Means Committee, which has jurisdiction over tax, trade, and a significant portion of Medicare.
Mr. Kimbell is an avid sportsman; fly fishing, hunting, and skiing at locales throughout the world when U.S. Congress is in recess. Mr. Kimbell serves as Chairman of the Safari Club International (SCI) Political Action Committee (SCIPAC), Chairman of the SCI Hunter’s Defense Fund (HDF), and sits on the SCI Government Affairs Committee.
Brett Knappe – Vice President, Business Services, Strategy and Integration, Medtronic
In his current role, Brett leads the integration management office (IMO) for Medtronic’s recent acquisition of Covidien, with responsibility for crafting a cohesive integration strategy and incorporating it into Medtronic’s broader corporate strategy. Brett is also working with Medtronic leadership to develop, communicate and execute our VBHC strategy, ultimately targeting a series of collaborative partnerships that leverage devices, data, services, mobility and other assets to improve global healthcare outcomes. Prior to his current role, Brett led Strategy and BD for Medtronic’s United States region. In this capacity, Brett took a lead role on MDT’s acquisition and integration of Cardiocom, forged a number of strategic provider partnerships, and led the company’s participation in the BPCI program. Brett has spent the past 10 years focused on corporate strategy and business development, with leadership positions in a number of prominent organizations including McKinsey and Co, 3M, CNH (Case New Holland) and most recently Medtronic. He has led multiple acquisitions and integrations in the health care industry, and has negotiated partnerships and strategic alliances across multiple industries. Brett earned a BS in Chemical Engineering from the University of Wisconsin, and an MS in Aerospace Engineering / Ph.D. in Mechanical Engineering from Stanford University.
Mark Leahey - President & CEO, MDMA
Mark Leahey is the President & CEO for the Medical Device Manufacturers Association (MDMA), a national trade association in Washington, DC that represents research-driven medical technology companies. Mr. Leahey's responsibilities include advocating on behalf of the entrepreneurial sector of the medical device industry to Congress, the Food and Drug Administration (FDA), the Centers for Medicare and Medicaid Services (CMS), and other federal and state agencies. He has lobbied for a more reasonable user fee for smaller companies, worked to open access to the hospital marketplace by challenging the exclusionary and anti-competitive nature of certain large group purchasing organizations (GPOs), as well as ensure that medical device technologies are reimbursed adequately. Mr. Leahey currently sits on the Medical Devices Committee for the Food and Drug Law Institute (FDLI) and the Editorial Advisory Board of Medical Product Outsourcing. He is a member of the Massachusetts Bar and a graduate of Georgetown University, the Georgetown Law Center and Georgetown’s McDonough School of Business.
Jinny Lee - Vice President of Strategic Marketing, Advanced Technology, Edwards Lifesciences
Jinny Lee is the vice president of strategic marketing for the advanced technology division of Edwards Lifesciences where she oversees strategy and marketing for the company’s new structural heart disease programs. She joined the company in 2001 where she was responsible for overseeing product development and global marketing for all areas in heart valve therapy including repair and replacement initiatives for the mitral, aortic and tricuspid valves. Previously she held positions of increasing responsibility in marketing and product development at Biocoll Laboratories and later GenSci Orthobiologics where she helped develop and launch multiple products for the spine and orthopedic markets and partnered with Depuy Acromed, a Johnson and Johnson Company, in the sales efforts. She started her career at the US Food and Drug Administration in the public affairs group located in Southern California. She earned her Bachelor of Science degrees in Biological Sciences and Environmental Analysis and Design and a MBA from the University of California, Irvine.
Kim Letch - Assurance & Advisory Partner, Ernst & Young LLP
Kim Letch, energetically leads Ernst & Young’s Strategic Growth Markets practice in Orange County. Kim has more than 20 years of experience providing assurance and business advisory services to clients in the life sciences, medical device, pharmaceutical, healthcare and financial services industries. Kim has experience serving and supporting clients with EY in Chicago, San Diego, Orange County, England and Australia. She is committed to working with emerging and fast growing companies through IPO and other strategic transactions.
Bill Link, PhD - Managing Director, Versant Ventures
Bill Link is a Managing Director specializing in early-stage investing in medical devices at Versant. Prior to co-founding Versant Ventures, Bill was a general partner at Brentwood Venture Capital. With more than two decades of operations experience in the healthcare industry, he has a proven record of building and managing large, successful medical product companies. His extensive knowledge of medical devices, particularly in ophthalmology, has contributed to Versant’s recognized leadership in this specialty area.
Perhaps Bill’s greatest operational success was as founder, chairman and CEO of Chiron Vision, a subsidiary of Chiron Corporation specializing in ophthalmic surgical products, which was sold to Bausch and Lomb in 1997. Prior to Chiron Vision, Bill founded and served as President of American Medical Optics (AMO), a division of American Hospital Supply Corporation, which was sold to Allergan in 1986. Later Bill served on the Board of AMO’s successor company, Advanced Medical Optics (AMO) which was acquired by Abbott in 2009. Before entering the healthcare industry, Bill was an Assistant Professor in the Department of Surgery at the Indiana University School of Medicine.
Dr. Frank Litvack - General Partner, Reprise Medical Technologies
Frank Litvack M.D. received his undergraduate and medical education at McGill University and completed a residency in Internal Medicine at McGill in 1982. From 1982-1985 he was a Fellow in Cardiovascular Medicine at Cedars Sinai Medical Center in Los Angeles and he joined the full time academic faculty there in 1985. From 1986 until 2000 he was Co-Director at the Cardiovascular Intervention Center at that institution.
Dr. Litvack attained the rank of Professor of Medicine at the UCLA School of Medicine and was board certified in three specialties- Internal Medicine, Cardiovascular Diseases and Interventional Cardiology. During his academic medical career he published extensively in various areas of research related to Interventional Cardiology. He is the author more than one hundred research articles and chapters. His primary focus was translational research involving novel therapies for patients with coronary artery and valvular heart disease including angioscopy, excimer laser angioplasty, valvuloplasty and drug delivery stents. Dr. Litvack has received several awards for his translational research including from the United States Space Foundation and the Space Technology Hall of Fame for “The Unique Secondary Use of NASA Technology” as related to medical development of the excimer laser and the Leon Goldman Medical Excellence Award for contributions to the field of biomedical optics. He left full time practice in 2000 to concentrate on entrepreneurial activities.
Dr. Litvack has founded or operated several successful life science companies including Progressive Angioplasty Systems that developed the stent delivery system for the Palmaz -Schatz stent marketed by Johnson & Johnson, Savacor a developer of implantable remote pressure monitoring devices that is now part of St Jude Medical, and Conor Medsystems a developer of drug delivery stents acquired by Johnson & Johnson in 2007.
He is General Partner in Reprise Medical Technologies a medical device incubator in Menlo Park California and is Chairman of Entourage Medical Technologies a developer of left ventricular access and closure devices for structural heart intervention. He serves on the Boards of several other life science companies in the areas of biotechnology, diagnostic tools and medical devices. He is a member of the Health Advisory Board of the RAND Corporation.
Jim Mazzo - Chairman and CEO, AcuFocus
Jim Mazzo is the Executive Chairman and CEO of AcuFocus. AcuFocus, a privately held ophthalmic medical device company, develops and markets breakthrough technologies for the improvement of near vision. Using the proven small aperture – or pinhole – effect, the company has developed two products: the Company’s flagship product which recently received FDA approval, the KAMRA™ corneal inlay and the innovative IC-8™ intraocular lens (IOL). The KAMRA inlay helps presbyopic patients restore their near vision while maintaining their distance vision. The IC-8 IOL provides a range of vision across various distances, from near to far, and is specifically designed for patients with cataracts. AcuFocus also distributes the AcuTarget HD instrument, an essential tool for optimizing treatment and technology selection for a broad range of patients, including LASIK, cataract, dry eye and presbyopes. Mr. Mazzo is also the Executive Chairman for Neurotech, a biotechnology company developing sight-saving therapies. Neurotech’s patented core technology platform, Encapsulated Cell Therapy (ECT), is a first-in-class, novel, versatile drug delivery platform in development for the treatment of a board array of eye diseases.
Dave Mildrew - Partner, Medical Device Practice, Healthcare IT Practice, BioQuest
Dave is a key member of the Medical Device, Healthcare IT, and Healthcare services practice groups. He uses his extensive background in human resources management with both large and small medical companies to identify and successfully place executive talent. Prior to BioQuest, Dave held Vice President, Human Resources positions with AccentCare, Tokos Medical, and Caremark. He began his career as a regional HR Manager with Pfizer recruiting sales and marketing executives and has been a Director of HR for Medtronic. He has prior executive recruiting experience as a Partner with McCormack & Farrow. Dave has an MS in Management from George Washington University and a BS in Business from Indiana University of Pennsylvania.
Michael A. Mussallem - Chairman & CEO, Edwards Lifesciences
Michael A. Mussallem has been chairman and chief executive officer since 2000 when the company spun-off from Baxter International. Prior to his current position, Mussallem held a variety of positions at Baxter from 1979 until 2000 with increasing responsibility in engineering, product development and general management. Currently, Mussallem serves on the boards and executive committees of the Advanced Medical Technology Association (AdvaMed) and the Healthcare Leadership Council. He is an advisory board member for the Leonard D. Schaeffer Center for Health Policy & Economics at the University of Southern California and a trustee of the University of California, Irvine Foundation. Mussallem is the former chairman of the board of directors of both AdvaMed and the California Healthcare Institute (CHI). Mussallem received a bachelor's degree in chemical engineering and also an honorary doctorate degree from the Rose-Hulman Institute of Technology in Terre Haute, Indiana.
Nate Raabe - Equity Sales, ROTH Capital Partners
Nathan Raabe joined Roth Capital Partners in 2014 to lead the venture group within the investment banking firm. Nathan has extensive experience in the healthcare market having served in both finance and operational roles. Prior to Roth, Nathan was part of the founding team of Sapheon, Inc, which was acquired by Covidien/Medtronic in 2014. At Sapheon, Nathan held various management roles in business development, sales, and marketing. In addition, Nathan spearheaded Sapheon’s fundraising efforts raising $40M through high net worth accredited investors. Prior to Sapheon, Nathan was president/CEO of various healthcare practice management companies, including Acamedic which was sold in 2009. Nathan graduated from Santa Clara University with a B.A in Finance.
Lieutenant Jason Redman, Navy SEAL
Former Lieutenant Jason Redman, a U.S. Army ranger and retired Navy SEAL, was shot 8 times, including in his face, just two weeks before he was due to return home from Iraq. After four years, 37 surgeries and 190 hours of general anesthesia, Jason gives a highly charged account of his combat missions in Iraq, the miraculous recovery from wounds that nearly killed him on the battlefield, and addresses the world-renown physicians and medical technologies that saved his life.
Redman, who spent eleven years enlisted as a Navy SEAL, was deployed to Columbia, Peru, Afghanistan and Iraq during his military career, serving as a team assault force commander. In western Iraq alone, he conducted forty capture-kill missions with his men and captured more than 120 Al Qaida insurgent leaders and fighters. But the high-stakes of combat are only part of his story. In September 2007, while leading a mission against a key senior Al Qaida commander in Iraq, Redman’s team was ambushed and he was gravely wounded. During the intense recovery that followed, Redman earned national media attention when he said, “Do not feel sorry for my wounds,” a statement that was symbolic for wounded warriors everywhere. Redman received numerous honors and awards, including the Bronze Star Medal with Valor, the Purple Heart, the Defense Meritorious Service Medal, the Navy Commendation Medal, the Joint Service Achievement Medal, five Navy Achievement Medals, and two Combat Action Ribbons.
Neil Riley - Managing Director, Equity Capital Markets, Piper Jaffray
Neil Riley is a managing director and a member of the Piper Jaffray equity capital markets group, exclusively focused on the healthcare sector for more than 13 years. His responsibilities include aiding corporate clients through the capital raising process and identifying the appropriate structure, valuation, size and timing. Additional responsibilities include coordinating the marketing, pricing, and institutional and retail distribution for new issue offerings. Riley has completed more than 100 bookrun transactions in healthcare for Piper Jaffray, representing $7.0 billion in capital raised.
Prior to joining Piper Jaffray, Riley was with KPMG LLP in both the assurance and corporate advisory practices.
Riley received a bachelor’s degree in accounting from the University of Wisconsin–Madison and is a Certified Public Accountant.
Adam Roth - Vice President, Investment Banking, ROTH Capital Partners
Adam Roth is a Vice President in the Investment Banking department. He joined the Institutional Sales group at ROTH in 2003, and transitioned to Corporate Finance in 2005. He has assisted in public and private equity financings in the healthcare, clean energy, and consumer sectors. Mr. Roth is currently a key participant in ROTH’s development of the OpenRound online investment platform, where accredited investors can obtain access to investments in early stage growth companies. Adam holds a degree in Business Administration from the University of Colorado.
Ted Roth - President & Head of Institutional Sales, ROTH Capital Partners
Ted Roth is President and Head of Institutional Sales for ROTH Capital Partners, LLC. He currently serves on the Boards of Directors of BioMed Realty Trust (NYSE: BMR), Targeson, Inc., Rady Children's Hospital and Health Center, CONNECT, and the San Diego Sports Commission (2005 Chairman). He is past Chair of the San Diego Regional Chamber of Commerce and the California Democratic Leadership Council, and was a member of the Board of Directors of the San Diego Padres Baseball Team.
Mr. Roth is a graduate of Iowa Wesleyan College, where he currently serves as a member of the Board of Trustees. He has a J.D. from Washburn University and an LL.M. from the University of Missouri in Kansas City.
Akhil Saklecha - Partner, Artiman Ventures
Focuses on early-stage investments with an interest towards medical technology. As a Partner at Artiman, he has led investments in CellMax Life, DMS Networks and HomeUnion. Akhil has over 15 years of experience in medicine and healthcare management. Prior to joining Artiman in 2010, Akhil was Medical Director of a 750 bed hospital's regional transfer program. Prior to that position, he was President and CEO of Canton Aultman Emergency Physicians, a professional services firm that provides physicians, mid-level providers, and coding expertise to multiple hospitals and urgent care centers. He was also Chairman of Emergency Medicine at Aultman Hospital, a large trauma, cardiac, and stroke center seeing nearly 90,000 patients annually. In this same time period, Akhil has served at the local, state, and national levels within emergency medicine, healthcare quality, information technology, managed care, and emergency medical services.
He is an Assistant Professor in Emergency Medicine at Northeastern Ohio Universities College of Medicine and continues to practice on a part time basis at Good Samaritan Hospital in San Jose where he remains connected to clinical medicine, patients, and physicians.
Akhil graduated from the combined B.S./M.D. program at Northeastern Ohio Universities College of Medicine. He completed his residency in Emergency Medicine at Summa Health System. He is Board Certified in Emergency Medicine and is a Fellow of the American College of Emergency Medicine. He holds an M.B.A. from the University of Tennessee at Knoxville where he graduated Phi Beta Kappa.
Brent L. Saunders - CEO and President, Allergan
He previously served as Chief Executive Officer and President of Forest Laboratories and had served as a Director of Forest since 2011. Mr. Saunders has significant healthcare industry expertise and a proven track-record leading business transformations and integrations. Prior to Forest, he was chief executive officer of Bausch + Lomb, a leading global eye health company, serving in this capacity from March 2010 until August 2013. Mr. Saunders also held a number of leadership positions at Schering-Plough, including the position of president of Global Consumer Health Care and was named head of integration for the company’s merger with Merck & Co. and for Schering-Plough’s acquisition of Organon BioSciences. Before joining Schering-Plough, Mr. Saunders was a partner and head of Compliance Business Advisory at PricewaterhouseCoopers LLP. Prior to that, he was chief risk officer at Coventry Health Care and senior vice president, Compliance, Legal and Regulatory at Home Care Corporation of America. Mr. Saunders began his career as chief compliance officer for the Thomas Jefferson University Health System. Mr. Saunders serves on the Board of Trustees of the University of Pittsburgh. He is also the former Chairman of the New York chapter of the American Heart Association. He is a member of the Business Council and PhRMA. Mr. Saunders, 45, earned his MBA from Temple University School of Business, his J.D. from Temple University School of Law and his bachelor’s degree from the University of Pittsburgh.
Dr. Joseph M. Smith - MD, CMO & CSO, West Health Institute
In his role as chief medical and science officer of the West Health Institute, Dr. Joseph M. Smith brings strategic, engineering and clinical expertise to advance West Health’s mission to pioneer new and smarter technologies, policies and practices, to make high-quality healthcare more accessible at a lower cost, with a focus on making successful aging a reality for all seniors.
Dr. Smith has an extensive career at the intersection of clinical medicine and engineering. Prior to joining the Institute, he was vice president of emerging technologies for Johnson & Johnson in their corporate office of science and technology. He also served as senior vice president and chief medical officer of Guidant/Boston Scientific’s Cardiac Rhythm Management. Prior to accepting leadership roles in the industry, Dr. Smith was a practicing cardiologist for almost two decades, starting at the Brigham and Women’s hospital in Boston, with sub-specialty training in clinical cardiac electrophysiology. Dr. Smith also established the Arrhythmia Institute in Fairfax, VA, which specializes in interventional cardiac electrophysiology and clinical research.
Named one of “20 People Who Make Healthcare Better” by HealthLeaders Magazine in 2010, Dr. Smith serves as faculty at the University of Southern California; an advisor to Johns Hopkins Biomedical Engineering; the Harvard-MIT Division of Health Science and Technology; the Wellcome Trust; and on the boards of directors of a number of innovative healthcare and technology start-up companies.
Dr. Smith holds a B.E.S from Johns Hopkins University, a Ph.D. in medical engineering and medical physics from the Harvard-MIT Division of Health Sciences and Technology, and an M.D. from Harvard Medical School. He is a fellow of the American College of Cardiology, the American Heart Association and the American Institute for Medical and Biological Engineering.
Brian Stewart - Founder and Managing Member, Innovo Ventures; Former General Manager of Patient Safety Technologies at Stryker
Brian Stewart is the Founder and Managing Member of Innovo Ventures where he focuses on healthcare investments. Prior to founding Innovo Ventures, Brian was the General Manager of Patient Safety Technologies at Stryker where he led the operations, strategic direction, product development and post-acquisition integration efforts of this business unit created as the result of Stryker's acquisition of Patient Safety Technologies, Inc., a publicly traded medical device company of which he was previously President and Chief Executive Officer. Brian was the founder and Chief Executive Officer of SurgiCount Medical, which he sold to Patient Safety Technologies in 2005. Brian's background also includes over 15 years of private equity and investment banking experience at firms including Donaldson, Lufkin & Jenrette, CIBC World Markets, Strome Investments and Credit Suisse. He has been granted numerous domestic and international medical device related patents and has been a guest lecturer at the Anderson School of Management at UCLA. Brian received a BA in Economics from UCLA and an MBA from the Anderson School of Management at UCLA.
Paul Symczak - Vice President of Entrepreneurship, OCTANe
Paul joined the OCTANe team in July 2013. He is a seasoned senior management executive with diverse experience in the telecom, wireless, online, high tech and broadcast media industries. He is most recently the co-founder and operator of Prism Strategic Consulting LLC and has been actively involved with the CONNECT Springboard mentoring program – a sister organization to the LaunchPadTM SBDC. Previously, Paul held senior business development, strategic alliances and operational positions with Verizon, GTE and Qualcomm, working in subsidiaries focused on leading edge and innovative products and services, and non-profit organizations, including serving as Senior Vice-President, General Counsel and Board Secretary for the Corporation for Public Broadcasting in Washington DC authorized by Congress to promote and support the growth of public broadcasting in the US. Paul’s education includes a J.D. from the George Washington University Law School and a BA in Economics from the University of Pittsburgh.
Dr. Richard Van Etten, Director, Chao Comprehensive Cancer Center, UC Irvine Medical Center
Dr. Richard Van Etten is a fellowship-trained hematologist and oncologist who specializes in the treatment of leukemia and other blood disorders. As director of the Chao Family Comprehensive Cancer Center, he leads a team of more than 200 physicians, scientists and other health science professionals. Van Etten's research lab studies the pathogenesis and therapy of human blood cancers, with particular emphasis on myeloid and lymphoid neoplasms that are associated with dysregulated tyrosine kinases.
As an medical student and doctoral candidate in biophysics at Stanford University, Van Etten worked on the molecular genetics of mammalian mitochondrial DNA with biochemist David A. Clayton, PhD. After postgraduate training in internal medicine and hematology at Brigham & Women's Hospital in Boston, he was a postdoctoral fellow under Nobel laureate David Baltimore, PhD, at the Whitehead Institute in Boston.
Van Etten went on to become a physician at Brigham & Women's Hospital and a faculty member in the departments of genetics and medicine at Harvard Medical School until 2003, when he joined Tufts University as professor of medicine. At Tufts, he held several positions, including leader of the Hematologic Malignancies Program and member of the graduate programs in Genetics, Immunology, & Molecular/Cellular Physiology at Tufts University. He assumed his first cancer center leadership role at Tufts Cancer Center in 2007 as acting associate director for clinical sciences and was appointed director in 2009. Van Etten became director of the Chao Family Comprehensive Cancer Center on Oct. 1, 2013.
James Villeneuve - Consul General, Canada
James Villeneuve was appointed Consul General of Canada, Los Angeles in February 2014. He is Canada's senior representative in Southern California, Arizona and Nevada.
Prior to his appointment, Mr. Villeneuve worked for Anheuser Busch InBev, the world’s largest brewing company and the parent company of Labatt Breweries, for more than 27 years. He started with Labatt in Toronto in sales and marketing and was later transferred to Vancouver, where he was regional director of government affairs for Western Canada.
In 1995, Mr. Villeneuve returned to Toronto to manage Labatt’s rebranding initiative and to run the company’s corporate and sports properties. He later became director of corporate affairs and then vice-president of corporate affairs for Canada. From 2007 to 2009, Mr. Villeneuve worked in Brussels to lead InBev’s global corporate affairs practice. After InBev purchased Anheuser Busch in 2009, Mr. Villeneuve moved to St. Louis to lead the company’s North American corporate affairs department.
Mr. Villeneuve has served on many boards during his career, including the Toronto Economic Development Commission, the Metro Toronto Convention Centre, the 2008 Toronto Olympic Bid, the Granville Island Trust, the Association of Canadian Advertisers, Carleton University, the Canadian Club, Teach for America, the United Way and the Regional Chamber and Growth Association in St. Louis. He received a Bachelor’s degree from Carleton University in 1985. Mr. Villeneuve is married to Kim Walker-Villeneuve and they have two children, Grace and Andrew.
David Walker - Partner, Dorsey
David Walker is a partner in Dorsey’s Intellectual Property group. He received an M.S. in Molecular Biology (Neuroendocrinology) from the University of Denver, where he focused on the molecular evolution and protein biochemistry of the neuropeptide prohormone Prodynorphin, and a B.A. in Biology from the University of Denver. After graduate school, David worked at the National Jewish Medical and Research Center, where he conducted research on the oxidative regulation of inflammation and immunity in the lungs, and at the University of Colorado School of Medicine, where he conducted research relating to the discovery of the causative agent of Multiple Sclerosis. He received his J.D. from The University of Denver Sturm College of Law.
Brett Wall - President, Neurovascular, Medtronic
Brett Wall serves as President of the Neurovascular business at Medtronic, which is part of the company’s Restorative Therapies Group. Brett, a seasoned medical device executive with 25 years of experience in the industry, manages a team of more than 1,000 individuals, including all business functions across all geographies.
Prior to joining Medtronic, Brett served as Covidien’s President, Neurovascular and International, where he managed all commercial activities and functions of the business resulting in a doubling of revenue from 2011 to 2015. Previously, Brett served as Senior Vice President and President, Neurovascular and Senior Vice President and President, International at ev3, Inc. From 2000 to 2008, Brett held positions of Vice President, Marketing for the Neurovascular and Peripheral Vascular divisions at Micro Therapeutics until its merger with ev3.
Previously, Brett worked at Boston Scientific as the Director of Marketing, Cardiovascular, Asia Pacific and Marketing Manager, Japan, where he was responsible for the Interventional Cardiology product lines within the Asia-Pacific region. Brett’s career in the medical device industry has also featured positions of increasing responsibility at C.R. Bard, where he was responsible for marketing the company’s entire suite of urological products.
Brett currently serves on the board executive committee for OCTANe, a group that promotes technical growth and expertise in the greater Orange County, California area. He is also a member of the CEO Roundtable at the University of California, Irvine. Previously, Brett served as Chairman of the Heart and Stroke Ball for the American Heart Association, Orange County Chapter.
Brett earned his bachelor’s degree in Comprehensive Business Administration with an emphasis in Marketing from the University of Nebraska at Kearney. He is a resident of Southern California.
Scott Whitcup, MD - CEO, Akrivista
Dr. Scott Whitcup is founder of Whitcup Life Sciences, LLC focused on the assessment, development, and commercialization of novel technologies addressing unmet medical need and he most recently assumed the position of CEO of Akrivista, a start-up in the ophthalmology industry. Previously, Dr. Whitcup was the Executive Vice President, R&D and Chief Scientific Officer at Allergan where he lead the discovery and global development of both pharmaceutical products and medical devices in therapeutic areas including ophthalmology, CNS, urology, dermatology, medical aesthetics, anti-infectives, and surgical obesity. Key product approvals included Botox® for chronic migraine, upper limb spasticity, and crow’s feet lines; Restasis® for dry eye; Alphagan® Lumigan®, and Combigan® for glaucoma; Ozurdex® for diabetic macular edema; and Juvederm Voluma® for facial aesthetics. Dr. Whitcup was also in charge of the global medical affairs organization and built the technology assessment group to support Allergan’s business development activities. Dr. Whitcup has 17 issued and 20 pending US patents and over 300 issued and pending international patents. Before Allergan, Dr. Whitcup was the Clinical Director at the National Eye Institute at the NIH, where he led its intramural clinical research program, and headed an immunology lab in the Clinical Branch.
Clay Wilemon – Chief Executive and Chief Strategy Officer, DevicePharm
Clay Wilemon is the Chief Executive and Chief Strategy Officer and founder of DevicePharm. He has vast experience in healthcare marketing with medical device and pharmaceutical companies, biotech and life sciences firms. Clay is a graduate of Vanderbilt University. He has provided strategic marketing counsel to numerous publicly traded companies during their startup, pre-IPO periods. He currently serves on the boards of two investor-backed medical device companies.